<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the vemurafenib, with lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THEOPHYLLINE " rxcui="10438">
<ATC code="R03DA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
